Nul, a British health tech startup building an “alcohol reduction platform”, has secured a $1m (£730,000) seed round led by the venture arm of Daily Mail and General Trust (DMGT).
The startup is developing a digital health platform that combines clinical care and prescription medication with digital pathways and behavioural support to reduce alcohol consumption.
The idea is similar to GLP 1, an appetite suppressing hormone used in popular weight-loss medications such as Ozempic. Nul’s programme is built around naltrexone, which plays on reward pathways and is used to reduce alcohol cravings.
Nul’s programme is delivered remotely through a subscription service supported by virtual clinical support.
“Alcohol reduction is one of the largest and least modernised areas in healthcare,” said Matus Maar, founder and chief executive of Nul.
“Telehealth and online pharmacy platforms have transformed categories like weight loss and mental health, yet alcohol has been left behind despite the scale of the problem. Nul is about making evidence-based treatment accessible, discreet and compatible with real life.”
Nul launched a UK test phase last summer and has so far onboarded more than 120 customers. Now backed by seed funding, the group is working towards a full commercial launch and an expansion of its team.
“We are delighted to be partnering with Matus and the rest of the Nul team. Nul’s mission to empower individuals to take control of their relationship with alcohol is both timely and transformative,” said Rachel Muzyczka, a partner at DMG Ventures.
“Their approach is not only innovative but deeply aligned with the growing demand for healthier lifestyles. We see tremendous potential in their approach and the market they’re serving.”
Additional funding came from BYVP and angel backers.
